ENTA

Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs for viral infections and liver diseases. The company has expertise in protease inhibitors and nucleotide analogs, with development programs targeting respiratory syncytial virus (RSV), hepatitis B virus, and non-alcoholic steatohepatitis (NASH). Enanta has a successful track record, having developed protease inhibitors for hepatitis C that were commercialized through partnerships. The company maintains an internal research and development operation while partnering with larger pharmaceutical companies for commercialization.